Luphere Depot_3.75mg-Inj.

※ DWRXs Differentiation Points 1) Maximize compliance in the form of minitablets. 2) Containing simethicone to remove foam in the colon, enabling smooth colonoscopy. 3) Maximizes the convenience of taking medication, and low water intake. ※Development Strategy 1) Non-clinical trial (KR) and patent applica...

Botulinum toxin type A  
Indication: Glabella Lines (Approved in KR, US, CA, EU), Post Stroke Upper Limb Spasticity, Crow's feet, Blepharospasm, Benign Masseteric Hypertrophy (Approved in KR)
- Nabota is the only 900kDa Neurotoxin approved in the US and EU since Botox.- It has demonstra...

Microneedle is the most active and evolved form of transdermal drug delivery. Its formulation utilizes micro-sized (usually under 1mm in length) needles to deliver drugs past the stratum corneum. CLOPAM is Daewoong Therapeutics' exclusive and patented manufacturing technology that ensures efficient drug ...

Envlo (Enavogliflozin) is a best-in-class SGLT2 inhibitor for T2DM. 
Highlights of Envlo are: 
* Launched in Korea from May 2023
* Approved by Korea MFDS in 2022 for T2DM 
* T2DM Phase III was completed in Korea as a monotherapy and in combinations with other anti-diabetics (du...

Fexuclue (Fexuprazan) is the best-in-class novel anti acid secretion agent with rapid onset time and potent acid suppressive effect, addressing the growing unmet needs of PPIs

Highlights of Fexuclue are: * Launched in Korea (2022) and Philippines (2023)
* Approved in Chile and Ecuador qq...

Luphere Depot (Leuprorelin) is a generic specialty drug of Lupron/Leuplin. Luphere Depot is a marketed product in Korea since January 2005. Currently, Luphere Depot is under development for US and Japan.

 

Key Features:

1) Mode of action: GnRH Agonist

2...

Olmesartan medoxomil, Rosuvastatin

Indication: Concomitant Hypertension and Dyslipidemia

<World's 1st fixed dose combination of olmesartan and rosuvastatin>
1. Developed with Daewoong's patented formulation technology
2. Indicated for the treatment of both hypertensio...

25, 50, 100, 200, 250, 300mg - Tab., Soft Cap., Hard Cap.

UDCA (Ursodeoxycholic Acid)

Indication:
Cholestasis(include PBC, PSC), Viral hepatitis C, Gallstone

URSA improves liver function in chronic hepatitis patients, improves symptom and histopathology in Cholestatis...

It contains an overall introduction to Daewoong Bio's bio plant's milestones, manufacturing facilities, and production capacity.

We continue to take the initiative by making bold challenges and investments in R&D to leap forward as a global healthcare group. Following the 2022 launch of Fexuclue, a drug treating gastroesophageal reflux disease, the company released Envlo, a Type 2 diabetes treatment. By bolstering its R&D pipeline, Daewoong Pharmaceutical is developing first-in-class and best-in-class drugs.